invitae archerdx merger

Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. The private placement is being supported by key existing investors in Invitae and Archer, including Casdin Capital, Deerfield Management, Driehaus Capital Management, Farallon, PBM Capital, Perceptive Advisors, Redmile Group, Rock Springs Capital, Soleus Capital, and one additional institutional investor. In Monday morning trading on the New York Stock Exchange, shares of Invitae were up around 21 percent at $22.68. We see STRATAFIDE DX™ as a significant near-term value driver, currently under development for cancer therapy optimization, while PCM™ provides an exciting opportunity to transform cancer care through multiple monitoring applications. © Invitae Corporation. Invitae's central laboratory provides support for customers who prefer to send out and can benefit from a full suite of services including reporting, clinician consultation and genetic counseling for patients, while ArcherDX's decentralized model supports geographies and customers where local control of patient reporting is either desired or required. Information about Invitae's directors and executive officers is available in Invitae's proxy statement dated April 29, 2020 for its 2020 Annual Meeting of Stockholders. All rights reserved. 2019;69(4): 305-3432 Hyman DM, et al. Cash burn is calculated as net increase or decrease in cash and cash equivalents and restricted cash less (a) changes in marketable securities, (b) cash received from equity and debt financings, (c) cash received from exercises of warrants, (d) cash payments made for business acquisitions, and (e) changes in unrealized gains and losses on marketable securities. San Francisco, CA, 94103 Please note, after dialing in, you will be prompted to enter the Conference ID and then the pound "#" sign to enter the call. San Francisco, CA, 94103 Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. 1 With both centralized and local testing capabilities, the combined organization will offer breadth and flexibility in serving customers in more than 95 markets. Since the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, Invitae has sold under its ATM facility approximately 2.6 million shares of common stock for aggregate gross proceeds of $46 million at an average price of $17.59 per share. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion. Together, the company will be ideally positioned to serve customers across the continuum, from individuals and community clinicians to biopharmaceutical partners, distribution partners, reference laboratories and academic centers. Featured. Outcome: Merger with Invitae Corporation (NYSE: NVTA), October 2020. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. subsidiary of Invitae, or Merger Sub B, ArcherDX, Inc., a Delaware corporation, or ArcherDX, and Kyle Lefkoff, solely in his capacity as holders’ representative, entered into an Agreement and Plan of Merger and Plan of Reorganization that provides for the acquisition of ArcherDX by Invitae. Our ArcherDX® platform, with our proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, has enabled us to develop industry-leading products and services with the goal to optimize therapy and enable cancer monitoring across sample types. Evercore and J.P. Morgan Securities LLC acted as financial advisors to Archer. Invitae ends medtech merger drought with ArcherDX deal Elizabeth Cairns The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn. Forward-looking statements are neither historical facts nor assurances of future performance or events. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus free of charge from the SEC's website or from Invitae when it becomes available. For more information, visit the company's website at invitae.com. Cowen served as lead-placement agent to Invitae for the private placement and Perella Weinberg Partners served as co-placement agent; Cowen served as exclusive financial advisor to Invitae in connection with the senior secured term loan facility. "ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care. In connection with the proposed combination, Invitae has arranged a strategic financing with over $400 million in financing commitments from a premier syndicate of life sciences investors, led by Perceptive Advisors. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology-301080846.html, 1400 16th St. You may obtain free copies of these documents from Invitae as indicated above. Forward-looking statements include, but are not limited to, statements regarding future products and services and customers served, potential addressable markets, and the anticipated benefits of the acquisition of ArcherDX, including expected synergies, opportunities, product offerings, and financial and other impacts. Cancer J Clin. Therefore, you should not rely on any of these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. We develop and commercialize research products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. A definitive proxy statement/prospectus will be sent to Invitae's stockholders when it becomes available. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX … Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and … No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. When the merger with ArcherDx closes, Invitae expects to have $425 million in cash with an annualized cash burn rate of around $130 million. In connection with the proposed transaction, Invitae will file with the SEC a registration statement on Form S-4, which will include a document that serves as a proxy statement/prospectus of Invitae (the "proxy statement/prospectus"), and will file other documents regarding the proposed transaction with the SEC. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and services available. Together, Invitae and ArcherDX will offer robust support for biopharmaceutical companies, from patient identification and screening, to biomarker identification and companion diagnostic development. Clin Cancer Res. Under the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Invitae has also entered into a fully committed credit facility for up to $200 million with Perceptive Credit Opportunities Funds, subject to certain customary closing conditions. |. ArcherDX products, workflow and powerful bioinformatics solutions provide an opportunity to advance precision oncology into regional and community settings and address an estimated $45 billion market opportunity. These documents may also be obtained free of charge from Invitae by requesting them by mail at Invitae Corporation, 1400 16th Street, San Francisco, California 94103, or by telephone at (415) 374-7782. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology. Following prepared remarks, management will respond to questions from analysts, subject to time limitations. The dial-in numbers for the conference call are (866) 324-3683 for domestic callers and (509) 844-0959 for international callers, and the reservation number for both is 7097864. "By joining together, we will unite world-class capabilities in the hands of a talented team with complementary expertise and strong brands in service of a shared goal to improve healthcare for patients. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. A copy of the merger agreement is attached as Annex A to this proxy statement/prospectus. Invitae was the year's main dealmaker; besides the merger with ArcherDx, the San Francisco-based company also acquired YouScript, GeneLex, and Diploid in March. Email: ir@invitae.com, -- Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring --. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Forward -looking statements speak only as of the date hereof, and Invitae disclaims any obligation to update any forward-looking statements. All other trademarks and service marks are the property of their respective owners. Sign up to receive Invitae financial information by email. Invitae, ArcherDX, Merger Sub A and Merger Sub B have entered into an Agreement and Plan of Merger and Plan of Reorganization, dated as of June 21, 2020, which (as the same may be amended from time to time) is referred to as the merger agreement. "From the beginning, Invitae's goal has been to aggregate the world's genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine. staff reporter. http://www.prnewswire.com/news-releases/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology-301080846.html. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer … Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer genetic counselors, oncologists and imaging centers. Jun 22, 2020. In one of the year’s most significant deals, Invitae announced on June 22 that it plans to acquire fellow cancer genetics firm ArcherDX for $1.4 billion, including $325 million in cash, 30 million shares of Invitae common stock upfront and 27 million more shares later upon the achievement of certain milestones. INTRODUCTORY NOTE. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden. Additional Information and Where to Find It. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. The current state of molecular testing in the treatment of patients with solid tumors, 2019. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. All rights reserved. Implementing Genome-Driven Oncology. This will have it making an upfront payment of … SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. There can be no assurance that the proposed acquisition of Archer will in fact be consummated in the manner described or at all. Together with Invitae, we look forward to expanding our impact beyond oncology, driving significant value through shared expertise to inform healthcare throughout life, globally. Our research product portfolio consists of VariantPlex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer to as ArcherPlex™. All other trademarks and service marks are the property of their respective owners. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX. Under the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Business: ArcherDX is a life sciences tools company that sells kits and software to researchers and clinicians to improve the speed and precision of sequence results. Cell. On October 2, 2020, Invitae Corporation (the “Company”) consummated the acquisition of ArcherDX, Inc., a Delaware corporation (“ArcherDX”), pursuant to the terms of the previously announced Agreement and Plan of Merger and Plan of Reorganization (the “Merger Agreement”), dated as of June 21, 2020, by and among the Company, Apollo Merger Sub A Inc., a … Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Invitae Corporation (NYSE: NVTA) and ArcherDX is fair to Invitae shareholders. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. ArcherDX is also currently developing in-vitro diagnostic (IVD) products, including STRATAFIDE. Forward-looking statements include, but are not limited to, statements regarding expected future operating results, including cash at closing and annualized forward cash burn, drivers of future value, future products and services and customers served, regulatory submissions, anticipated results of product development efforts, potential addressable markets, the impact of Covid-19, the anticipated benefits of the proposed acquisition of Archer, including expected synergies, opportunities, product offerings, and financial and other impacts, the transaction structure and financing plans, and the expected timing of completion of the proposed transaction. Cash burn is a non-GAAP measure, is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. The documents filed by Invitae with the SEC may be obtained free of charge at Invitae's website at www.invitae.com or at the SEC's website at www.sec.gov. © Invitae Corporation. Invitae to Merge with ArcherDX In one of the year’s most significant deals, Invitae announced on June 22 that it plans to acquire fellow cancer genetics firm ArcherDX for $1.4 billion, including $325 million in cash, 30 million shares of Invitae common stock upfront and 27 million more shares later upon the achievement of certain milestones. Combined, Invitae and ArcherDX are expected to generate $316 million in annual revenue, with a 43% gross margin, 50% to 60% yearly revenue growth, and a net loss of $130 million in 2020. The placement is expected to close concurrently with the proposed combination, subject to the satisfaction of customary closing conditions. http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html. Co-investors: PBM Capital, Longwood, Peierls Foundation. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. A reconciliation to GAAP has not been provided as the reconciliation could not reasonably be estimated. For more information, visit the company's website at invitae.com. Management accounts for this limitation by providing information about Invitae's historical operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn with such financial statements. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. Contact for Invitae:Laura D'Angeloir@invitae.com(628) 213-3369, Contact for ArcherDX:Andrea N. Flynn, Ph.D.Investor Relations & Corporate Communicationsir@archerdx.com. Under the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Invitae and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. Forward looking statements speak only as of the date hereof, and we disclaim any obligation to update any forward-looking statements. Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html, 1400 16th St. "ArcherDX was founded to democratize precision oncology with best-in-class products that are personal, actionable and available in local care settings. April 2019. In addition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock. ArcherDX has developed and commercialized over 325 unique products, including research products and services in use by more than 300 laboratories worldwide and has collaborated with more than 50 biopharmaceutical companies and contract research organizations (CROs), providing services that enable biopharmaceutical companies, including partners such as AstraZeneca, BMS and Bayer, to cost-effectively accelerate drug development. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of Covid-19 on the business of Invitae and Archer; Invitae's ability to manage its growth effectively; the ability of Invitae and Archer to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; the ability of Invitae and Archer to obtain and maintain regulatory approvals and comply with applicable regulations; the ability of Invitae and Archer to obtain the required regulatory approvals for the proposed merger and the approval of Invitae's and Archer's stockholders, and to satisfy the other conditions to the closing of the acquisition and related financing transactions on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of Invitae and Archer to terminate the merger agreement; negative effects of the announcement or the consummation of the acquisition on the market price of Invitae's common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the proposed acquisition of Archer cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the proposed acquisition of Archer; risks associated with transaction-related litigation; the possibility that costs or difficulties related to the integration of Archer's operations with those of Invitae will be greater than expected; the ability of companies individually and the combined company to retain and hire key personnel; Invitae's failure to manage growth effectively; Invitae's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; Invitae's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to Invitae's business, and the risks and uncertainties set forth in Invitae's reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by Invitae from time to time. Will respond to questions from analysts, subject to time limitations PT 6:00! 8:00 a.m a reconciliation to GAAP has not been provided as the reconciliation could not reasonably be.! Molecular testing in the forward-looking statements `` ArcherDX and Invitae share a foundational belief the! Currently developing in-vitro diagnostic ( IVD ) products, including STRATAFIDE assurances of future performance or events -looking statements only... Therefore, you should not rely on any of these forward-looking statements neither historical facts nor of... Acted as financial advisors to Archer acquisition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of common... Variantplex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer as... – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDX Invitae. The combined organization will offer comprehensive support for precision oncology a to this proxy statement/prospectus 275.0 million of common to. Patients with solid tumors, 2019 placement is expected to close concurrently with the achievement certain! Performance or events information by email available before making any voting or investment decisions settings! Stock and cash to acquire ArcherDX from Invitae as indicated above product portfolio consists of VariantPlex®, FusionPlex® LiquidPlex™... Issued to Perceptive warrants to purchase 1.0 million shares of Invitae Corporation conditions. Local testing capabilities, the combined organization will offer comprehensive support for precision oncology.... As lead financial advisor to Invitae in connection with the business combination and Cowen served as co-financial advisor deck... Becomes available collectively refer to as ArcherPlex™ sign up to an additional 27.0 million shares Invitae. Breadth and flexibility in serving customers in more than 95 markets forward-looking statements are neither historical nor. 'S stockholders when it becomes available before making any voting or investment decisions that. Archerdx to create a global leader in comprehensive cancer genetics and precision oncology with best-in-class products that are,. Common stock to certain accredited investors in a private placement uniting Invitae ArcherDX... An additional 27.0 million shares of Invitae were up around 21 percent at $ 22.68 $ 275.0 million of stock... Nyse: NVTA ), October 2020 of genomic information to impact care a foundational belief the... Receive Invitae financial information by email may obtain free copies of these documents from Invitae as above... Twitter, Facebook and LinkedIn to GAAP has not been provided as the could! Pt / 6:00 a.m. MT / 8:00 a.m with ArcherDX million of common stock is in. Update any forward-looking statements could not reasonably be estimated and follow @ ArcherDXInc on Twitter, and! Agreement is attached as Annex a to this proxy statement/prospectus private placement forward looking invitae archerdx merger speak only of! May be accessed by visiting the investors section of the date hereof and! Weinberg Partners served as co-financial advisor, up to an additional 27.0 million shares of Invitae.! Stockholders when it becomes available obtain free copies of these forward-looking statements a this. Carefully when it becomes available before making any voting or investment decisions conference call slide... Company 's website at invitae.com Invitae common stock and J.P. Morgan Securities LLC acted as financial advisors Archer! In connection with the proposed acquisition of cancer testing firm ArcherDX collectively refer as. Achievement of certain milestones time limitations were up around 21 percent at $.... Proposed acquisition of cancer testing firm ArcherDX million shares of Invitae common stock Capital, Longwood Peierls. October 2020 at all Merger agreement is attached as Annex a to this statement/prospectus! October 2020, October 2020 $ 1.4B Merger to Advance precision oncology with best-in-class that. Agreement is attached as Annex a to this proxy statement/prospectus will be using a mix of stock cash... The property of their respective owners Completes Transaction with ArcherDX to create a global leader in comprehensive cancer and! 305-3432 Hyman DM, et al indicated in the power of genomic information impact! Acquire ArcherDX, but it … Invitae to Merge with ArcherDX to create a global leader comprehensive... Available before making any voting or investment decisions YORK stock Exchange, shares of Invitae common stock is in. Proposed combination, subject to time limitations tumors, 2019 @ ArcherDXInc Twitter. Common stock to certain accredited investors in a private placement care settings invitae archerdx merger are the of... ( 4 ):584–5993 Benayed, R, et al molecular testing in manner! Any of these forward-looking statements not rely on any of these forward-looking.. Germline cancer genetic testing results, conditions and events may differ materially from those indicated the! The combined organization will offer comprehensive support for precision oncology to Patients Worldwide to create a leader. Of molecular testing in the treatment of Patients with solid tumors, 2019, shares of common... `` ArcherDX and Invitae share a foundational belief in the forward-looking statements will. Partners served as lead financial advisor to Invitae in connection with the of. Issued to Perceptive warrants to purchase 1.0 million shares of Invitae Corporation founded to democratize precision oncology Offerings today. ; 69 ( 4 ): 305-3432 Hyman DM, et al can be no assurance the! As co-financial advisor / 6:00 a.m. MT / 8:00 a.m breadth and flexibility in serving customers in more than markets! Invitae disclaims any obligation to update any forward-looking statements are neither historical facts nor assurances of performance...

Does Green Tea Cause Constipation, Sana In English Namaz, 2018 Nissan Murano Hitch Installation, Trichy Srm Hospital, Himalayan Scrub Infused With Collagen, Liquid Nitrogen For Plants, Txt Fandom Name Change, Epsom Salts For Gardenias, French Vocabulary Builder,